SOURCE: Masimo

Masimo

March 19, 2015 08:01 ET

Masimo to Showcase Root® Solutions for the OR and ICU at the International Anesthesia Research Society's 2015 Annual Meeting and International Science Symposium

IRVINE, CA--(Marketwired - Mar 19, 2015) - Masimo (NASDAQ: MASI) announced today that the world's top anesthesiologists will see how Masimo's Root® patient monitoring and connectivity platform is transforming patient care in the operating room and the intensive care unit at the International Anesthesia Research Society's 2015 Annual Meeting and International Science Symposium in Honolulu, Hawaii, March 21-24.

Root integrates Masimo's SET® Measure-through Motion and Low Perfusion™ pulse oximetry and breakthrough noninvasive rainbow® measurements -- including continuous, noninvasive hemoglobin (SpHb®) technology -- in an integrated, clinician-friendly platform. With a dock for the Radical-7® handheld monitor, an instantly interpretable display, and multiple networking/connectivity options, Root integrates multiple streams of data on an easy-to-read, touch-screen.

Root innovations include:

  • MOC-9™ - Flexible measurement expansion through Masimo Open Connect™ (MOC-9™) with MOC-9 modules from Masimo or third-party measurement by other companies to expand the platform's measurements and capabilities. New MOC-9 modules in the U.S. will require new 510(k) clearances
  • Capnography - ISA™ CO2 sidestream module featuring fast warm up time and the innovative and cost-effective Nomoline™ sampling line
  • Iris™ - Built-in connectivity gateway through Iris™ for standalone devices such as IV pumps, ventilators, hospital beds, and other patient monitors to the EMR
  • Wireless functionality - Capable of transmitting information through Bluetooth and Wi-Fi
  • Raidus-7™ - The first and only wearable, wireless monitor with Masimo's breakthrough rainbow® SET® technology, offering patients continuous monitoring with freedom of movement. Studies have shown that patient mobility is a key factor in more rapid patient recovery.1 Radius-7 allows clinicians to continuously monitor their patients when they are mobile.

Root also offers Masimo's SedLine® brain function monitoring, which provides four channels of EEG to help clinicians better understand the effects of anesthesia on the brain. SedLine measures the effects of anesthesia and sedation by monitoring both sides of the brain's electrical activity. As such, SedLine provides a wealth of EEG-based data, which can help clinicians monitor anesthesia.

At IARS, Masimo will host two events with leading anesthesiologists:

"The Elderly Brain and the Pediatric Brain During General Anesthesia and Emergence: From Neurobiology to Electroencephalography" non-CME symposium is 1:30 p.m., March 21, Coral 1, Hilton Hawaiian Village.

Moderator: Dr. Aryeh Shander, M.D., FCCM, FCCP, chief of the Department of Anesthesiology, Critical Care Medicine, Pain Management and Hyperbaric Medicine at Englewood Hospital & Medical Center in Englewood, N.J.

Presenters:

  • Dr. Emery Brown, M.D., PhD, professor of anesthesia at Massachusetts General Hospital/Harvard Medical School;
  • Dr. Patrick L. Purdon, PhD, assistant professor of anesthesia, Harvard Medical School; and
  • Michael Avidan, MBBCh, professor of anesthesiology and cardiothoracic surgery, Washington University School of Medicine, St. Louis, Mo.

Team Masimo Japan also will host an evening event at 6:30 p.m., March 21, Sheraton-Waikiki.

Presenters:

  • Makoto Ozaki, professor and chairman of the Department of Anesthesiology at Tokyo Women's Medical University, will deliver the opening remarks;
  • Dr. Emery Brown, M.D., PhD of Massachusetts General Hospital/Harvard Medical School, will lead a special session, "A New Look at Using the EEG to Monitor the Brain States in the Anesthetized Patient";
  • Maiko Hasegawa, senior assistant professor, Department of Anesthesiology and Critical Care Medicine at Kagoshima University Medical and Dental Hospital, will offer a clinical report on Root and SedLine.

1 Needham D, Korupolu R, Zanni J, Pradhan P, Colantuoni E, Palmer J, Brower R, Fan E. "Early Physical Medicine and Rehabilitation for Patients With Acute Respiratory Failure: A Quality Improvement Project." Archives of Physical Medicine and Rehabilitation Vol 91, Issue 4, PP 536-542, April 2010

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com. @masimoinnovates

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that SedLine helps anesthesia providers deliver the desired level of targeted sedation throughout all phases of anesthesia; risks related to our assumptions of the repeatability of clinical results obtained; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.

Contact Information